Alzheon: Data justify pursuit of homozygous AD patients

Alzheon Inc. (Framingham, Mass.) said tramiprosate improved cognition in mild to moderate Alzheimer's disease patients homozygous for apolipoprotein E epsilon 4 ( APOE4) in a subgroup analysis of two earlier Phase III studies. Alzheon said the results support its plan to develop ALZ-801, an oral small molecule prodrug of tramiprosate, for homozygous patients.

Alzheon said homozygous APOE4 patients account for 10-15% of the total AD population. ...